Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.12 USD
Change Today 0.00 / 0.00%
Volume 0.0
NNAB On Other Exchanges
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

nanoantibiotics inc (NNAB) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/28/15 - $0.55
52 Week Low
08/5/15 - $0.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NANOANTIBIOTICS INC (NNAB)

Related News

No related news articles were found.

nanoantibiotics inc (NNAB) Related Businessweek News

No Related Businessweek News Found

nanoantibiotics inc (NNAB) Details

NanoAntibiotics, Inc., a developmental stage biotechnology company, discovers, develops, and commercializes various broad spectrum antibiotics for gram-negative and gram-positive bacterial infections in the United States. It is involved in developing various pharmaceutical candidates, including methicillin-resistant staphylococcus aureus, drug-resistant tuberculosis, drug-resistant enterococcus, and drug-resistant streptococcus pneumonia; and nano efflux pump blocker and nano antibiotic drug candidates. The company was founded in 2013 and is based in Beverly, Massachusetts.

1 Employees
Last Reported Date: 09/24/14
Founded in 2013

nanoantibiotics inc (NNAB) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $150.0K
Compensation as of Fiscal Year 2014.

nanoantibiotics inc (NNAB) Key Developments

NanoAntibiotics Deleted From OTCBB

NanoAntibiotics, Inc.’s common stock deleted from OTC Bulletin Board effective October 20, 2014 on account of ineligible for quotation on OTCBB due to quoting inactivity under SEC Rule 15c2-11.

NanoAntibiotics Provides Update on Novel Efflux Pump Inhibitor

NanoAntibiotics reported successful preliminary in vitro results on its novel efflux pump inhibitor. The current study involved testing for efflux pump inhibition in Staphylococcus epidermis, a common gram-positive bacterium. In the study, the bacteria were incubated with a tracer dye to observe real time monitoring of its membrane transport systems. The results showed that the bacteria treated with efflux pump inhibitor demonstrated retention of the tracer dye, whereas no dye retention was observed in the untreated bacteria. Further studies are ongoing. The company is excited about these results and its continuing progress to identify and optimize key nano efflux pump inhibitors to target and block some of the most deadly gram-positive and gram-negative bacteria.

NanoAntibiotics Seeks Acquisitions

NanoAntibiotics Inc. is looking for acquisition opportunities. It intends to use its net proceeds from any area to acquire complementary compounds. However, it does not have plans for any acquisitions at this time.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NNAB:US $0.12 USD 0.00

NNAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NNAB.
View Industry Companies

Industry Analysis


Industry Average

Valuation NNAB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANOANTIBIOTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at